Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in ChinaPuyuan Xing, Junling Li, Tao Xin et al.|Targeted Oncology|2019Cited by 14
Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patientsQiaoyun Tan, Yuankai Shi, Ruyun Gao et al.|Cancer Immunology Immunotherapy|2024Cited by 10
Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort studyPuyuan Xing, Junling Li, Di Ma et al.|Chinese Journal of Cancer Research|2019Cited by 9
Clinical features and outcomes of<i>ALK</i>rearranged non‐small cell lung cancer with primary resistance to crizotinibDi Ma, Junling Li, Yan Zhang et al.|Thoracic Cancer|2019Cited by 6